Tempus AI's first quarterly profit of $5.6m came from below the operating line — a $75.9m operating loss met $102.8m of other income, mostly marks on listed shares; for the half year that line is only $75.0m
Q2 2026 10-Q: revenue $382.5m (+22%), operating loss $75.9m (from $61.8m), net income $5.6m. The profit rests on other income of $102.8m, whose source is $216.4m of publicly traded shares remeasured every quarter. The quarter also carries an $11.6m loss on debt extinguishment and $2.9m of equity-method losses. First-half operating cash flow was −$80.8m, receivables of $360.9m equal 94% of quarterly revenue, and first-half stock-based compensation of $106.8m is 15% of revenue
aiSwingX™ Editorial · Reviewed
Published
Tempus AI Form 10-Q for Q2 2026 (as of June 30): statement of operations (operating loss, other income, loss on debt extinguishment, equity-method losses), cash-flow statement (gain on marketable equity securities, stock-based compensation), Note 15 Fair Value Measurements and Marketable Equity Securities, balance sheet (receivables, cash) and the revenue and liquidity sections of MD&A
aiSwingX™ analyzes US filings and reports them as news investors can read.
–
1 0
Tempus AI (TEM) reported second-quarter 2026 revenue of $382.5m, up 22%, and swung from a $42.8m net loss a year earlier to **net income of $5.6m**. Reading down the income statement in the 10-Q filed on July 24 shows where that profit came from: the operating result is a loss of $75.9m, and the line beneath it, other income net, is $102.8m.
What happened
Tempus AI (TEM) sequences tumours for cancer patients and licenses the resulting data to pharmaceutical companies and researchers.
Its quarterly report (10-Q) for Q2 2026 shows revenue of $382.5m, up 22% from $314.6m: genomics $289.3m and data and applications $93.2m ($72.8m a year earlier). Total cost and operating expenses were $458.4m, leaving an operating loss of $75.9m, wider than the $61.8m of a year earlier.
The lines below tell the quarter's story: interest income $3.9m, interest expense −$10.3m, a loss on debt extinguishment of −$11.6m, and other income, net of +$102.8m. That produces pre-tax income of $8.8m; after tax of −$0.3m and equity-method losses of −$2.9m, net income is $5.6m. A year earlier the same quarter showed a $42.8m net loss.
What the numbers meanSubscribers
Why it mattersSubscribers
Company explanation and contextSubscribers
What to watchSubscribers
Arithmetic table · quarterly metricsSubscribers
End of the free preview
What the numbers mean — for subscribers
We find the numbers that are in the filing but not in the news, and analyze what they mean, how big they are and what to watch next quarter — with the arithmetic and quarterly metrics. Cancel any time.
Net income of $5,642k for Q2 2026 is what the income statement reports. This article shows which lines produced it: an operating loss of $75,913k, then other income net of $102,757k, and in the cash-flow statement the company reverses a $66,166k first-half gain on marketable equity securities as a non-cash item.
Does other income recur at this level?
The filing's own numbers say no. Other income was $102,757k in Q2 but $75,048k for the first half, which means the line was negative in Q1. The assets being marked are publicly traded shares, so the direction changes with their prices.
How is the operating business doing?
Revenue was $382.5m (+22%), of which data and applications contributed $93.2m ($72.8m a year earlier) and genomics $289.3m. Total cost and operating expenses were $458.4m, more than revenue. First-half operating cash flow was −$80.8m.
Where can I verify these numbers?
On SEC EDGAR: the Q2 2026 Form 10-Q (accession 0001193125-26-326090) — 'Loss from operations', 'Other income, net' and 'Loss on debt extinguishment' in the statement of operations, 'Gain on marketable equity securities' in the cash-flow statement, Note 15 Fair Value Measurements and Marketable Equity Securities, and the liquidity section of MD&A.
How aiSwingX™ wrote this
We read the filing on SEC EDGAR in full — statements, notes, MD&A. Press releases and news are not used as sources.
Every figure is reconciled to its location in the filing and to XBRL data. One mismatch means no publication.
An editor reviews before publication; any later change is recorded in the revision history.
Tempus AI Form 10-Q for Q2 2026 (as of June 30): statement of operations (operating loss, other income, loss on debt extinguishment, equity-method losses), cash-flow statement (gain on marketable equity securities, stock-based compensation), Note 15 Fair Value Measurements and Marketable Equity Securities, balance sheet (receivables, cash) and the revenue and liquidity sections of MD&A · SEC EDGAR · This article is not investment advice. Disclaimer
Frequently asked questions
Where can I verify the figures in this article?
Open the filing cited at the bottom of the article (e.g. the 10-Q note number) on SEC EDGAR via the link at the end of the article.
What is the at-a-glance box?
A four-item summary of the article: the key figure, what it means, the source, and what to watch next quarter. If you are short on time, read just that.
May I quote or share this article?
Customary quotation and sharing are fine with attribution (aiSwingX™ and the article URL). Republishing the full text elsewhere requires the License plan.
aiSwingX™ analyzes US filings and reports them as news investors can read.
